NEUROENDOCRINE CARCINOMAS (NEC)
Clinical trials for NEUROENDOCRINE CARCINOMAS (NEC) explained in plain language.
Never miss a new study
Get alerted when new NEUROENDOCRINE CARCINOMAS (NEC) trials appear
Sign up with your email to follow new studies for NEUROENDOCRINE CARCINOMAS (NEC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody drug targets Hard-to-Treat neuroendocrine cancers
Disease control Recruiting nowThis study tests a new drug, peluntamig (PT217), in people with advanced neuroendocrine cancers like small cell lung cancer. The drug is designed to attach to two proteins (DLL3 and CD47) found on cancer cells, potentially helping the immune system attack them. The trial will fir…
Matched conditions: NEUROENDOCRINE CARCINOMAS (NEC)
Phase: PHASE1, PHASE2 • Sponsor: Phanes Therapeutics • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Experimental drug tarlatamab takes on rare, Tough-to-Treat cancer
Disease control Recruiting nowThis phase 2 trial is testing a drug called tarlatamab in 60 adults with advanced extrapulmonary neuroendocrine carcinoma, a rare cancer that has come back after standard chemotherapy. Tarlatamab works by helping the body's immune cells find and attack cancer cells. The main goal…
Matched conditions: NEUROENDOCRINE CARCINOMAS (NEC)
Phase: PHASE2 • Sponsor: Inkeun Park • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC